New combo therapy aims to halt spread of nasopharyngeal cancer
NCT ID NCT04944914
First seen May 07, 2026 · Last updated Jun 23, 2026 · Updated 9 times
Summary
This phase 3 trial tests whether adding a precise form of radiation (SBRT) to the immunotherapy drug camrelizumab helps control cancer better than camrelizumab alone in people with nasopharyngeal cancer that has spread to a few spots (oligometastatic). About 188 adults whose primary tumor is under control and who have had at least one round of chemotherapy will be randomly assigned to one of two groups. The main goal is to see how long patients live without their cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
camrelizumab (an immunotherapy drug) and stereotactic body radiotherapy (SBRT, a precise type of radiation)
What this could lead to
If successful, this could show that adding targeted radiation to immunotherapy helps control cancer spread better than immunotherapy alone, potentially improving how long patients live without their cancer getting worse.
What could go wrong
This is a phase 3 trial, but it is still recruiting and results are not yet known. The combination may cause more side effects than immunotherapy alone, and it is only tested in a specific group of patients with limited metastases.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.